Carbamazepine toxicity - Revision history

Elcatracho: /* Background */

2021-02-11T23:35:54Z

Background

← Older revision		Revision as of 23:35, 11 February 2021
Line 1:		Line 1:
	==Background==		==Background==
	*Has [[Anticholinergic Toxicity\|anticholinergic]] and antiepileptic effects		*Has [[Anticholinergic Toxicity\|anticholinergic]], sodium-channel blockade, anti-NMDA and antiepileptic effects
	*Therapeutic concentration: 4-12 mg/L		*Therapeutic concentration: 4-12 mg/L

2020-11-29T22:52:28Z

Clinical Features

← Older revision		Revision as of 22:52, 29 November 2020
Line 13:		Line 13:
	*Cardiovascular		*Cardiovascular
	**Dysrhythmias are rare but may occur		**Dysrhythmias are rare but may occur
	**[[Wide QRS]] ~~2/2~~ sodium channel blockade<ref>Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).</ref>		**[[Wide QRS]] from sodium channel blockade<ref>Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).</ref>
	**[[QT Prolongation]]		**[[QT Prolongation]]

2020-11-29T22:52:10Z

Clinical Features

← Older revision		Revision as of 22:52, 29 November 2020
Line 13:		Line 13:
	*Cardiovascular		*Cardiovascular
	**Dysrhythmias are rare but may occur		**Dysrhythmias are rare but may occur
	**[[Wide QRS]]		**[[Wide QRS]] 2/2 sodium channel blockade<ref>Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).</ref>
	**[[QT Prolongation]]		**[[QT Prolongation]]

2016-08-15T02:48:25Z

2016-08-15T02:47:30Z

Disposition

← Older revision		Revision as of 02:47, 15 August 2016
Line 32:		Line 32:
	==Disposition==		==Disposition==
	*Consider discharge for patient with decreasing levels (measured few hrs apart) and is asymptomatic		*Consider discharge for patient with decreasing levels (measured few hrs apart) and is asymptomatic

			==See Also==
			*[[Toxicology (main)]]

	==References==		==References==

2016-08-15T02:47:10Z

Evaluation

2016-08-15T02:46:39Z

Clinical Features

← Older revision		Revision as of 02:46, 15 August 2016
Line 4:		Line 4:

	==Clinical Features==		==Clinical Features==
			''May be delayed and follow crescendo-decrescendo course (due to delayed GI motility)''
	*May be delayed and follow crescendo-decrescendo course (due to delayed GI motility)		*Neurologic
	*~~CNS~~		**[[Ataxia ]]
	**Ataxia
	**Nystagmus		**Nystagmus
	**Seizures		**[[Seizures]]
	**Coma		**[[Coma ]]
	*[[Anticholinergic Toxicity]]		*[[Anticholinergic Toxicity]]
	*CV		*Cardiovascular
	**Dysrhythmias are rare but may occur		**Dysrhythmias are rare but may occur
	**[[Wide QRS]]		**[[Wide QRS]]

2016-08-15T02:45:59Z

← Older revision	Revision as of 02:45, 15 August 2016
(No difference)

2016-08-11T18:50:53Z

Management

← Older revision		Revision as of 18:50, 11 August 2016
Line 25:		Line 25:
	**Consider [[Multidose activated charcoal]]		**Consider [[Multidose activated charcoal]]
	*[[Dialyzable Drugs\|Dialysis]] for severe cases. Indications: <ref>Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.</ref>		*[[Dialyzable Drugs\|Dialysis]] for severe cases. Indications: <ref>Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.</ref>
	**Intractable seizures or life threatening dysrhythmia (level 1D recommendation )		**Intractable seizures or life threatening dysrhythmia (level 1D recommendation)
	**Respiratory depression requiring mechanical ventilation or prolonged coma (level 2D suggestion)		**Respiratory depression requiring mechanical ventilation or prolonged coma (level 2D suggestion)
	**Significant toxicity or rising/persistent carbamazepine level despite [[activated charcoal]] and supportive care (level 2D suggestion)		**Significant toxicity or rising/persistent carbamazepine level despite [[activated charcoal]] and supportive care (level 2D suggestion)

2016-08-11T18:50:16Z

Management

← Older revision		Revision as of 18:50, 11 August 2016
Line 23:		Line 23:
	*GI decontamination		*GI decontamination
	**[[Activated Charcoal]] (if presents within 1hr of ingestion)		**[[Activated Charcoal]] (if presents within 1hr of ingestion)
			**Consider [[Multidose activated charcoal]]
	*[[Dialyzable Drugs\|Dialysis]] for severe cases. Indications: <ref>Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.</ref>		*[[Dialyzable Drugs\|Dialysis]] for severe cases. Indications: <ref>Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.</ref>
	**Intractable seizures or life threatening dysrhythmia (level 1D recommendation )		**Intractable seizures or life threatening dysrhythmia (level 1D recommendation )